Homrich & Berg’s iBio IBIO Stock Holding History

Homrich & Berg’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20	Closed	-$20K	–	403
2020 Q3	$20K	Buy	+20	New	+$29K	﹤0.01%	339

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Homrich & Berg's IBIO Position: Q4 2020 in Review

Homrich & Berg sold out of iBio (IBIO) in Q4 2020, closing a stake of 20 shares — an estimated $20K sold.

Homrich & Berg first reported a position in IBIO in Q3 2020 and held it in 1 quarter. The position peaked at $20K in Q3 2020. 89 funds tracked by Wall St. Rank hold IBIO as of Q4 2020.

Homrich & Berg reported no remaining iBio position as of Q4 2020 after selling out during the quarter.
Homrich & Berg sold 20 iBio shares in Q4 2020, an estimated $20K.
Homrich & Berg first reported a position in iBio in Q3 2020 and held it in 1 quarter.
Homrich & Berg's iBio position peaked at $20K in Q3 2020.
89 funds tracked by Wall St. Rank held iBio as of Q4 2020.

Based on Homrich & Berg's 13F filing for Q4 2020, filed 16 Feb 2021.